<DOC>
	<DOCNO>NCT00976469</DOCNO>
	<brief_summary>The purpose study determine prefer dose H1N1 pandemic influenza vaccine pediatric population , age 6 month 17 year , base upon assessment immunogenicity safety .</brief_summary>
	<brief_title>A/H1N1 Immunogenicity Safety Infants , Children Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Written inform consent provide subject 's parent ( ) / legal guardian ( ) ( accord national law ) Written assent provide subject accord age capacity understand Subject 9 17 year ( Stratum A ) , 3 8 year ( Stratum B ) , 12 35 month ( Stratum C ) 6 11 month age ( Stratum D ) time screen Subject bear full term pregnancy ( &gt; = 37 week ) birth weight &gt; = 2 kg ( Strata C D ) Subject / parent ( ) / legal guardian ( ) understand ( ) nature study / willing comply requirement protocol ( e.g . return followup visit , completion subject diary ) If female childbearing potential , subject present negative urine pregnancy test within 24 hour prior first vaccination agree employ adequate birth control measure duration study Subject generally healthy , determine investigator 's clinical judgment collection medical history performance physical examination Subject physically mentally capable participate study Subject participate another clinical study involve investigational drug , biological product device within 30 day prior study enrollment schedule participate another clinical study involve investigational drug , biological product device course study Subject history exposure A/H1N1/California/07/2009 virus history vaccination A/H1N1/California/07/2009 antigen closely related influenza virus antigen Subject inherit acquire immune deficiency Subject currently recent history significant neurological , cardiovascular pulmonary ( include asthma ) , hepatic , metabolic , rheumatic , autoimmune , hematological renal disorder Subject history test positive Human Immunodeficiency Virus ( HIV ) , Hepatitis B Surface Antigen ( HBsAg ) Hepatitis C Virus ( HCV ) . No confirmatory test previous infection virus conduct part clinical study . Subject disease currently undergoing form treatment undergoing form treatment within 30 day prior study entry could expect influence immune response . Such treatment include , limited systemic high dose inhale corticosteroid , radiation treatment , immunosuppressive cytotoxic drug . Subject history severe allergic reaction anaphylaxis Subject rash , dermatologic condition tattoo might interfere injection site reaction rating Subject receive blood transfusion immunoglobulin within 90 day study entry Subject receive live vaccine within 4 week inactivate vaccine within 2 week prior vaccination study Subject functional surgical asplenia Subject know suspect problem alcohol drug abuse Subject one subject 's parent ( ) / legal guardian ( ) dependent relationship one study team member . Dependent relationship include close relative ( i.e. , child , sibling , partner/spouse , parent ) well employee investigator site personnel conduct study Subject pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>